Tiara™ Transcatheter Mitral Valve program featured in
multiple scientific presentations
NASDAQ: NVCN
TSX: NVC
WASHINGTON, DC, Sept. 15, 2014 /PRNewswire/ - Neovasc
Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)
(TSX: NVC) announced today that its Reducer™ technology was
featured in a "live case" broadcast on Sunday, September 14, 2014 at the 26th Annual
Transcatheter Cardiovascular Therapeutics (TCT) scientific
symposium. A Clinical update on the company's Tiara™
transcatheter mitral valve (TMVI) program was also presented. TCT
is the world's largest educational meeting specializing in
interventional cardiovascular medicine and is being held
September 13th
-17th, 2014 in Washington
DC.
In a live case broadcast in the main arena of the conference,
Dr. Marc Jolicoeur and Dr.
Serge Doucet of Montreal Heart
Institute (Montreal, Canada)
successfully implanted a Neovasc Reducer in the coronary sinus of a
79-year-old patient suffering from severe refractory angina. The
implantation was completed successfully, without any
procedural complications. The Neovasc Reducer gained CE mark in
2011. It is indicated for use in the treatment of patients
diagnosed with refractory angina, a painful and debilitating
condition that occurs when the coronary arteries deliver an
inadequate supply of blood to the heart muscle, despite treatment
with standard revascularization or cardiac drug
therapies.
"This live case broadcast of a Reducer implantation in a patient
with complex cardiovascular disease and no other therapeutic
options demonstrates the ease and utility of the procedure as a
means to provide relief of debilitating angina symptoms in this
patient population," commented Neovasc CEO, Alexei Marko, "Early compassionate use
experience with our Tiara TMVI device, developed for the treatment
of mitral regurgitation, is also encouraging and we look forward to
the commencement of our TIARA-I Feasibility trial which is expected
to begin in later 2014".
Neovasc's Tiara transcatheter mitral valve was also featured in
multiple scientific sessions at TCT and Dr. Anson Cheung, Professor of Surgery and Director
of Cardiac Transplant at St.
Paul's Hospital, Vancouver
Canada presented an update on the Tiara transcatheter mitral
valve clinical program. Dr. Cheung indicated that the Tiara valve
has now been successfully implanted in three patients under
compassionate use.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Tiara™
technology in development for the transcatheter treatment of mitral
valve disease, the Neovasc Reducer™ for the treatment of refractory
angina and a line of advanced biological tissue products that are
used as key components in third-party medical products including
transcatheter heart valves. For more information, visit:
www.neovasc.com.
Statements contained herein that are not based on historical
or current fact, including without limitation statements containing
the words "anticipates," "believes," "may," "continues,"
"estimates," "expects," and "will" and words of similar import,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. Such forward looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Such factors include,
among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company
operates; the merits and the Company's defence of the lawsuits
filed by CardiAQ, listing of the Company's securities on the TSX,
our anticipated use of proceeds from any financings, a history of
losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product
candidates, ability to properly integrate newly acquired
businesses, technology changes; competition; changes in business
strategy or development plans; the ability to attract and retain
qualified personnel; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations;
liability and other claims asserted against the Company; and other
factors referenced in the Company's filings with Canadian
securities regulators. Although the Company believes that
expectations conveyed by the forward-looking statements are
reasonable based on the information available to it on the date
such statements were made, no assurances can be given as to the
future results, approvals or achievements. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as
otherwise required by applicable law.
SOURCE Neovasc Inc.